Medical/Pharmaceuticals

The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics

SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, ...

2021-10-18 22:42 744

Professor Carl June, the "Pioneer of CAR-T", Joined Bioheng Scientific Advisory Board

NANJING, China, Oct. 18, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd (hereafter Bioheng), announced that ProfessorCarl June, an authoritative cancer immunologist and "Pioneer of Chimeric Antigen Receptor T (CAR-T) cells," officially joined the Bioheng scientific advisory board and acted...

2021-10-18 21:00 690

I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...

2021-10-18 20:00 576

Concord Medical Is Shortlisted for the "5G+Healthcare" Pilot Project

BEIJING, Oct. 18, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone ...

2021-10-18 16:08 532

WuXi ATU Opens New Manufacturing Facility to Further Enhance Its CTDMO Services for Global Customers

PHILADELPHIA, Oct. 17, 2021 /PRNewswire/ -- WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Develop...

2021-10-18 11:05 580

Concord Medical Files 2020 Annual Report on Form 20-F

BEIJING, Oct. 15, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM ), a healthcare provider specialized in c...

2021-10-16 06:00 1971

Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma

HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...

2021-10-15 12:44 804

Roan Holdings Group Announces Agreement to Set Up Joint Venture to Expand in Consumer Health Services Market

BEIJING and HANGZHOU, China, Oct. 14, 2021 /PRNewswire/ -- Roan Holdings Group Co., Ltd. ("Roan" or the "Company") (OTC Pink: RAHGF and RONWF), a provider of diversified solutions in financial, insurance and healthcare related products and management services, today announced that the Company's s...

2021-10-14 20:00 630

BioAgilytix Closes Acquisition of Australia-based 360biolabs®

Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages DURHAM, N.C., Oct. 14, 2021 ...

2021-10-14 19:00 715

Qilian International Holding Group Limited Received Approval for Oxytetracycline API Export to Egypt

JIUQUAN, China, Oct. 13, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced that on September 14, 2021, through its subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd. (the "Gan...

2021-10-13 20:00 983

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China

* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...

2021-10-13 20:00 542

Shanghai, industry partners to co-build world-class biopharma industry cluster

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...

2021-10-13 19:43 499

The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...

2021-10-13 15:47 586

Accelerate Innovation Towards the Future,SAB of Winhealth Pharma Formally Established

HANGZHOU, China, Oct. 12, 2021  /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in m...

2021-10-12 23:45 939

Integrated Media Technology Limited Enters US$11 Million Conditional Agreement to Acquire an Internet of Medical Things (IoMT) Company

SYDNEY, Oct. 12, 2021 /PRNewswire/ -- Integrated Media Technology Limited (NASDAQ: IMTE) ("IMTE" or the "Company"), announces today the signing of a conditional sale and purchase agreement to acquire 100% equity interest in Magnum International Holdings Limited ("Magnum"), forUS$11 million which ...

2021-10-12 20:30 1131

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...

2021-10-12 20:30 591

Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform

SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...

2021-10-12 19:21 800

NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification

* Real-time PCR-based human papillomavirus (HPV) detection product is launched. * Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO,South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, annou...

2021-10-12 16:00 631

Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma

SUZHOU, China, Oct. 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (O...

2021-10-11 13:00 4991

Winhealth-CARD Cooperation Boosts Rare Disease Healthy Ecosystem Construction

BOAO, China, Oct. 8, 2021 /PRNewswire/ -- On September 30, 2021 (Hainan-Bo'ao), Hongkong Winhealth Pharma Group (Winhealth Pharma) and the China Alliance for Rare Disease (CARD) officially signed a five-year strategic collaboration agreement. The cooperation involved rare disease registration and...

2021-10-08 23:01 1923
12345 ... 276